MEK inhibitor breakthroughs in Noonan syndrome — the targeted MAPK pathway therapies demonstrating cardiac function improvement in children with severe hypertrophic cardiomyopathy, alongside Novo Nordisk's February 2026 FDA approval of once-weekly Sogroya (somapacitan) for Noonan-associated growth failure — represent the most transformative therapeutic innovations in this...

According to the latest report published by Data Bridge Market Research, the Selective Estrogen Receptor Modulator (SERM) Drug Market The global selective estrogen receptor modulator (SERM) drug market size was valued at USD 2.23 billion in 2025 and is expected to reach USD 3.60 billion by 2033, at a CAGR of 6.20% during the forecast period This Selective Estrogen Receptor Modulator...